Revance Therapeutics (RVNC)
(Delayed Data from NSDQ)
$3.53 USD
+0.58 (19.66%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $3.52 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RVNC 3.53 +0.58(19.66%)
Will RVNC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RVNC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVNC
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
RVNC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Other News for RVNC
Revance Therapeutics, Inc. (RVNC) Q2 2024 Earnings Call Transcript
Revance Therapeutics Reports Surge in Aesthetic Portfolio Growth
Revance price target lowered by $5 at Piper Sandler, here's why
Revance Therapeutics (RVNC) Receives a Buy from Piper Sandler
Revance Therapeutics: Strong Sales Trends and Undervalued Stock Justify Buy Rating